Efficacy and safety of dasatinib in patients with chronic myeloid leukemia in blast phase whose disease is resistant or intolerant to imatinib: 2-year follow-up data from the START program

被引：14

作者：

Ganibacoiti, Carlo ^{[1
]}

CorteS, Jorge ^{[2
]}

Kim, Dong-Wook ^{[3
]}

Dombret, Herve ^{[4
]}

Zhu, Chao ^{[5
]}

Van Tornout, Jan M. A. ^{[5
]}

Garzon, Felix T. ^{[5
]}

Baccarani, Michele ^{[6
]}

机构：

[1] McGill Univ, Montreal, PQ H3A 2T5, Canada

[2] MD Anderson Canc Ctr, Houston, TX USA

[3] Catholic Univ Seoul, St Marys Hosp, Seoul, South Korea

[4] Hop St Louis, Paris, France

[5] Bristol Myers Squibb Co, Wallingford, CT USA

[6] S Orsola Malpighi Univ Hosp, Bologna, Italy

来源：

关键词：

D O I：

10.1182/blood.V110.11.472.472

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

472

引用

页码：145A / 145A

页数：1